

**InMed**  
Pharmaceuticals

# Corporate Presentation

February 2022

 Nasdaq :INM

[www.inmedpharma.com](http://www.inmedpharma.com)



# Forward Looking Statements

This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: unlocking the full potential of cannabinoid pharmaceuticals; anticipated development activities, timelines, catalysts, and milestones; the potential benefits of product candidates; anticipated revenue and market opportunities; and the continued availability of key personnel. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.

With respect to the forward-looking information contained in this presentation, the Company has made numerous assumptions regarding, among other things: the development and integration of BayMedica’s business with InMed’s business; the market for cannabinoid based consumer health and wellness products; the development and launch of additional rare cannabinoids for the health and wellness market; continued and timely positive preclinical and clinical efficacy data; the speed of regulatory approvals; demand for the Company’s products; continued availability of key personnel; continued access to sufficient capital to fund operations; and continued economic and market stability.

These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others: the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results; risks associated with obtaining funding from third parties; risks related to the timing and costs of clinical trials; key personnel may become unable to serve the Company; the need for receipt of regulatory approvals; changes in regulations that are adverse to our business; and economic and market conditions may worsen. Readers are cautioned that the foregoing list is not exhaustive. A more complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Security and Exchange Commission on [www.sec.gov](http://www.sec.gov).


The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, except as required by law.



# InMed: Two Key Pillars



**A global leader in the manufacturing and clinical development of rare cannabinoids**



**Rare Cannabinoid Manufacturing**

**Pharmaceutical**

**Consumer Health & Wellness**

**Pharmaceutical Development Programs**




**Drug Development**

**Novel Cannabinoid Analogs**



# The Opportunity & Challenge of Rare Cannabinoids



- The 140+ rare cannabinoids occur in extremely low amounts in the cannabis plant
- The cost of extracting sufficient quantities of these cannabinoids can be prohibitive
- The challenge is how to manufacture sufficient quantity & purity to investigate, and potentially commercialize, rare cannabinoid-based therapies

Note: lists are not exhaustive



# Create shareholder value by combining complementary business models



## A Cannabinoid Pharmaceutical Company

- Pharmaceutical-grade, proprietary approach for synthesized cannabinoids (IntegraSyn™)
- Focused on therapeutic application of rare cannabinoids for the treatment of diseases with high unmet medical needs
- Strong preclinical/clinical evidence for two lead indications in dermatology and ocular diseases
- Highly experienced team in pharma drug development
- Nasdaq-listed, access to financial markets




## Manufacturer and Supplier to the Consumer Health & Wellness Market

- Proprietary manufacturing platforms for naturally occurring rare cannabinoids for the consumer Health and Wellness marketplace
- Sector-leading capabilities in synthetic biology and chemical synthesis
- Novel cannabinoid analogs for pharma R&D
- Early and growing revenue stream in nutraceuticals, more than **\$2.5M pre-acquisition cumulative sales**
- Leader in large batch production of the rare cannabinoid CBC – currently 200kg batches with ability to scale to metric tonnes
- Launched CBT in 1Q22
- Poised to launch additional high-margin rare cannabinoids for B2B sales in next 3-6 months






# Rare Cannabinoid Manufacturing






# Unparalleled Cannabinoid Manufacturing Expertise

## Biosynthesis




- Preferred for complex structures at very large scale
- Potential for high yield, lower COGS at volume
- Well suited for consumer health and wellness products
- Yeast (BayMedica) and bacteria (InMed) expertise.

## Chemical synthesis



- Preferred for CBs with simple structure and CB analog R&D
- Potential for less equipment / lower capital requirements
- Potentially easier validation
- Important component of secondary IntegraSyn™ cannabinoid differentiation step

## IntegraSyn™




- Utilizes very high efficiency, biosynthesis derived enzymes
- Flexibility to shift from production of one cannabinoid to a range of cannabinoids
- Commonly available and cost-efficient starting materials
- Easy to scale-up to mass production
- Shorter production time
- Higher yield = lower COGS

**No one manufacturing approach fits all: Multiple avenues to select most effective manufacturing method based on target cannabinoid and appropriate quality specifications for the desired market segment**

# Robust Pipeline of Rare Cannabinoids for Consumer Health & Wellness

## Launched: CBC & CBT

Multiple B2B customers in consumer health and wellness



## Pipeline

Plans to launch several rare cannabinoids

CBDV		THCV	
CBGV	CBGVA	CBNV	
CBx	CBy	CBz	

## Stage of Development

*Early 2022 Launch Planned*

*Scale-Up / Development*


*R & D*





# Cannabinoid Synthesis Demand Expected to Drive Exponential Market Growth

Global cannabinoid synthesis market estimated to grow from \$10B in 2025 to \$115B by 2040



Source: Raymond James, Sept 2020



# Cannabinoid Drug Development Programs

INM-755 and INM-088



## INM 755: Epidermolysis Bullosa (EB)

- Epidermolysis bullosa (EB) is a group of rare genetic skin diseases characterized by fragile skin that blisters easily from minimal friction that causes shearing of the skin layers.
- The most common form is EB Simplex (EBS), ~55% of all EB patients.
- The total EB population is estimated to be between 12,500 and 25,000 in the United States.
- No therapies approved specifically for the treatment of EB wounds and other symptoms.
- INM-755 is being developed for symptomatic relief in all EB patients and may have further utility in enhancing skin integrity in subset of EBS patients.



Photograph of Dystrophic EB



## INM-755: Positive Top-Line Results

### INM-755 Creams Safe & Well Tolerated on Intact Skin and Epidermal Wounds

- On intact skin (Study 101, n=22 healthy adult volunteers, 14 days):
  - Majority of subjects in all groups had no events on most days
  - Slightly higher incidence and severity of erythema (redness) and scaling (flaking skin) in groups receiving active creams compared to vehicle cream
- On epidermal wounds (Study 102, n=8 healthy adult volunteers, 14 days):
  - No differences in local reactions compared to controls
  - No adverse effects of INM-755 creams on wound healing

### Phase 2 Clinical Trial in EB Commenced

- First time CBN has advanced to a Phase 2 Clinical trial
- Study taking place at 13 sites in 8 countries. Patient screening and treatment on-going




Austria, France, Germany, Greece, Israel, Italy, Serbia and Spain



## INM-088: Potential Roles for CBN in Glaucoma

InMed data suggest CBN is the cannabinoid of choice for neuroprotection in the eye



Several cannabinoids demonstrate increased drainage, leading to reduced IOP

Glaucoma Market:

- Est. 76M people worldwide
- Est. US\$11B by 2027



### Target Effects of CBN


- Direct neuroprotection for the retina and optic nerve, independent of intraocular pressure (IOP) reduction
- Reduce IOP in the affected eyes via increased fluid drainage





# InMed data suggest CBN is the cannabinoid of choice for neuroprotection in the eye

## Ocular tissue distribution of INM-088 formulation *in vivo*



- *In vitro* studies demonstrated CBN protects the retinal ganglion cells from cell death under elevated pressure conditions
- *In vitro* studies indicated that CBN may be able to reduce intraocular pressure
- CBN appears to have a wide therapeutic window for neuroprotection
- Studies compared CBN with several other cannabinoids



# Pharmaceutical Programs: High-Level Time/Event Schedule

## INM-755: EB

- ✓ Report results from 755-102-HV
- ✓ Finalize and file regulatory submissions (CTAs) for 755-201-EB trial
- ✓ Finalize manufacturing methods and process to support 755-201-EB
- ✓ Produce clinical trial supplies
- ✓ Initiate 755-201-EB trial in multiple European jurisdictions
- ✓ Conduct KOL meetings and initial data screening to support 2nd indication for INM-755

✓ Completed    
 ✓ In-progress

## INM-088: Glaucoma

- ✓ Engage leading ocular clinical research organization to develop clinical game plan
- ✓ Scale-up INM-088 drug product (CBN+MiDROPS®)
- ✓ Publish key CBN data in peer-reviewed journal
- ✓ Complete pre-IND package and FDA Pre-IND Meeting (if needed)


Conduct non-GLP dose ranging studies

Initiate toxicology studies in preparation for clinical trials



## Extensive Patent Protection for Combined Company

Major opportunity for expansion of patent portfolio of new chemical entities



- A growing library of new analogs targeting diverse diseases
- Patent applications covering the biosynthetic pathway and semi-synthetic production of both natural cannabinoids and analogs
- Combined entity with 13 patent families (7 – manufacturing, 6 – product / formulations)
- Full commercial rights to IntegraSyn™ manufacturing approach



# Bringing Together a Depth of Cannabinoid Expertise



Extensive experience in pharma R&D, cannabinoid/API manufacturing, clinical and regulatory affairs, biotech strategic planning, product sales & marketing, and capital markets

**Eric A. Adams, MIBS**  
Chief Executive Officer

30+ years of experience in global biopharma leadership in BusDev, S&M with enGene, QLT, Abbott, Fresenius



**Bruce S. Colwill, CPA, CA**  
Chief Financial Officer

25+ years of financial leadership: General Fusion, Entrée Resources, Neuromed Pharma



**Alexandra Mancini, MSc**  
SVP, Clinical and Regulatory Affairs

30+ years of global biopharma R&D experience: Sirius Genomics, Inex Pharmaceuticals, and QLT



**Eric Hsu, PhD**  
SVP, Preclinical R&D

20+ years of scientific leadership experience in gene transfer technologies, formulation and process development: enGene Inc.



**Michael Woudenberg, PEng**  
VP, CMC

20+ years of engineering, scale-up and GMP manufacturing experience: Phyton Biotech, Arbutus Biopharma, 3M and Cardiome Pharma



**Shane Johnson, MD**  
SVP and General Manager BayMedica

20+ years strategic planning/ execution with LEK Consulting (Biogen Idec, Amgen, Genentech) Hamilton BioVentures



**Phil Barr, PhD**  
VP, Discovery Research

35+ years R&D leadership at Arriva Pharma (Founder) and Chiron. >50 issued patents; > 200 publications.



**Charles Marlowe, PhD**  
VP, Chemistry

30+ years R&D discovery-to-FDA approval: Millennium Pharma, COR, Chiron, Takeda, Dow Chemical, Exelixis.



**Jim Kealy, PhD**  
VP, Synthetic Biology

25+ years in synthetic biology and tech development at Amyris, Intrexon and Kosan Biosciences



**Chris Meiering, PhD**  
VP, Commercialization Operations

15+ years of scientific R&D and 20+ years of entrepreneurial leadership at Zuke's Pet Nutrition





## Financial Snapshot

Cash and Short-term Investments (2021-09-30)	\$15.3 M
Shares I/O	14.2 M
Options (2021-09-30)	0.9 M
Warrants	6.5 M
Fully Diluted Shares (2022-01-31)	21.6 M
Previous Close (2022-01-31)	US\$1.21
52-week High	US\$6.42
52-week Low	US\$0.92
Avg. Daily Volume (Trailing 50 Days)	313,855
Market Cap, I/O (2022-01-31)	US\$17.1 M

## Current Analyst Coverage

<b>H.C. Wainwright</b>	Raghuram Selvaraju
<b>Roth Capital Partners</b>	Scott Henry
<b>Edison Research Group</b>	Ken Mestemacher






## Looking forward to 2022 – Key Value Drivers



- Launch of several high demand CBs in the health and wellness space
- Improvement in manufacturing approaches to lower COGS
- Complete enrollment Phase 2 clinical trial in EB
- Advance glaucoma program towards human clinical trials
- Explore proprietary cannabinoid analogs for pharma targets
- Continue to build a significant IP portfolio

UNLOCKING THE POTENTIAL OF  
CANNABINOID MEDICINES



**InMed**  
Pharmaceuticals

+

**BAYMEDICA**  
A Division of InMed Pharmaceuticals

Thank you!

**Colin Clancy**

Senior Director,  
Investor Relations

cclancy@inmedpharma.com  
+1-604-416-0999

 **Nasdaq** :INM

[www.inmedpharma.com](http://www.inmedpharma.com)